Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$1.74

-0.01 (-0.57%)

, ATRA

Atara Biotherapeutics

$15.75

-0.4 (-2.48%)

15:41
10/19/16
10/19
15:41
10/19/16
15:41

CymaBay treatment of Primary Biliary Cholangitis granted PRIME status by EMA

The European Medicines Agency reports that its CHMP reviewed nine recommendations for eligibility to PRIME during its October meeting and three were granted and six were denied. CymaBay's (CBAY) MBX-8025 for the treatment of Primary Biliary Cholangitis was one of the three granted PRIME status, according to a post to the EMA's website. The other two were Albireo's A4250 and Atara Biotherapeutics' (ATRA) treatment of patients with Epstein-Barr Virus associated Post Transplant Lymphoproliferative Disorder in the allogeneic hematopoietic cell transplant setting who have failed on rituximab. Reference Link

CBAY

CymaBay

$1.74

-0.01 (-0.57%)

ATRA

Atara Biotherapeutics

$15.75

-0.4 (-2.48%)

  • 29

    Nov

CBAY CymaBay
$1.74

-0.01 (-0.57%)

06/01/16
HCWC
06/01/16
DOWNGRADE
Target $2.25
HCWC
Neutral
CymaBay downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded CymaBay Therapeutics to Neutral saying that while the primary biliary cholangitis study stopped early for strong efficacy, increases in transaminases renders the overall result uncertain. The analyst has a $2.25 price target for the shares.
07/01/16
ROTH
07/01/16
INITIATION
Target $4
ROTH
Buy
CymaBay coverage resumed with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv resumed coverage of CymaBay with a Buy rating and $4 price target.
ATRA Atara Biotherapeutics
$15.75

-0.4 (-2.48%)

03/29/16
SBSH
03/29/16
NO CHANGE
SBSH
Citi lays out potential targets for next biotech M&A wave
Citi analyst Yigal Nochomovitz believes the setup for the next acquisition cycle in the biotech space is here, but that biotech management's desire to do deals is the missing catalyst. He thinks another one-to-three quarters is needed before "reset valuations are better absorbed as the new reality." Large cap pharma and biotech companies are cash rich and have signaled repeatedly over last year that they are looking for new assets, Nochomovitz tells investors in a research note. He sees a "greater probability" of a takeover over the next 12-18 months for Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR). He sees a "moderate probability" of a takeover for Anthera (ANTH), Loxo Oncology (LOXO), MacroGenics (MGNX) and Mirati Therapeutics (MRTX). Nochomovitz also sees a "lower probability" of a buyout for Atara Biotherapeutics (ATRA), Chimerix (CMRX), Keryx (KERX) and Mirna Therapeutics (MIRN).
07/08/16
07/08/16
NO CHANGE

Atara unlikely to encounter same side effects as Juno, says JMP Securities
After the FDA placed Juno's (JUNO) lead clinical program, JCAR015, on hold, JMP Securities says that the side effects seen among Juno's patients probably won't be seen among Atara's patients. The firm keeps a $34 price target and Outperform rating on Atara.
09/15/16
GSCO
09/15/16
DOWNGRADE
Target $16
GSCO
Sell
Atara Biotherapeutics downgraded to Sell from Neutral at Goldman
Goldman Sachs analyst Salveen Richter downgraded Atara Biotherapeutics to Sell saying there are no major pipeline catalysts until late 2017. Further, the analyst views Atara's transition to in-house manufacturing by the end of 2016 as a risk pending FDA clearance. She cut her price target for the shares to $16 from $23.
09/15/16
09/15/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMC Networks (AMCX) downgraded to Hold from Buy at Stifel with analyst Benjamin Mogil citing weak industrywide ad trends for scripted shows after their first year. 2. Atara Biotherapeutics (ATRA) downgraded to Sell from Neutral at Goldman with analyst Salveen Richter saying there are no major pipeline catalysts until late 2017. 3. Helmerich & Payne (HP) downgraded to Hold from Buy at Argus with analyst Bill Selesky saying that the company is increasingly relying on lower priced spot contracts rather than higher priced term contracts. 4. Cognizant (CTSH) downgraded to Neutral from Buy at Goldman with analyst James Schneider saying cyclical headwinds in the company's Financials and Healthcare units will persist through the first ha lf of 2017. 5. Penske Automotive (PAG) downgraded to Hold from Buy at Gabelli citing the recent strength in shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.